RXi Pharmaceuticals (RXII) Set to Announce Quarterly Earnings on Wednesday

RXi Pharmaceuticals (NASDAQ:RXII) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 14th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

RXi Pharmaceuticals (NASDAQ:RXII) last released its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.16. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.02 million. On average, analysts expect RXi Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RXII traded up $0.04 during trading hours on Wednesday, reaching $0.46. 2,147,137 shares of the stock traded hands, compared to its average volume of 1,522,784. The firm has a market cap of $1.85 million, a price-to-earnings ratio of -0.11 and a beta of 2.07. RXi Pharmaceuticals has a fifty-two week low of $0.40 and a fifty-two week high of $7.70.

RXII has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of RXi Pharmaceuticals in a report on Monday, October 15th. ValuEngine upgraded shares of RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd.

TRADEMARK VIOLATION WARNING: This piece was published by WKRB News and is the property of of WKRB News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/11/07/rxi-pharmaceuticals-rxii-set-to-announce-quarterly-earnings-on-wednesday.html.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

See Also: Cash Flow

Earnings History for RXi Pharmaceuticals (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply